The global organ-on-chip market was valued at $103.44 million in 2020, and is estimated to reach $1,559.2 million by 2030, growing at a CAGR of 31.1% from 2021 to 2030.
Organ-on-chip is designed to replicate the natural physiology and mechanical stress that cells in the human body encounter.
The chips have real human cells lining them, and their tiny fluidic channels mimic blood and air movement in the human body. The chips flexibility allows them to mimic breathing patterns and muscle contractions. Each organ chip, including the lung, liver, intestine, or brain, is approximately the size of an battery that is typically used in small electronic devices.. Such devices produce multiple levels of tissues and organ functionalities, which are not possible using conventional 2D and 3D culture systems. Organ-on-chip offers a wide range of applications such as diseases modelling, patient stratification, and phenotypic screening. Researchers can see the organ's operation, behavior, and response at the cellular and molecular level because to the chip's transparency.
This market is majorly driven by increase in prevalence of the chronic disease across the globe, which, in turn, increases the demand for medications, leading to drug discovery, drug development, and animal testing. However, organ-on-chips are looked on as an alternative for animal testing due to stringent regulatory guidelines and its complexity. Wide availability of 3D models for in vitro testing,including lung-on-chip, heart-on-chip, liver-on-chip, and brain-on-chip is significantly driving the growth of the market.
Furthermore, in May 2021, the U.S. Food and Drug Administration (FDA) extendedits research collaboration with CN Bio Innovations Limited, one of the leading developers of single and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, for another three years to investigate the lung-on-a-chip model for inhaled drug evaluation applications.
Furthermore, growth in demand for personalized medicine, rise in pharmaceutical & biotechnology R&D, and government funding for various drugs, clinical trials for novel entities, and repurposing of the drugs are expected to drive the organ-on-chip market in the forecast period.
Market players have invested in developing organ-on-chip products for lung, heart, kidney, brain, liver, and gut that can aid in several disease treatments. For instance, Nortis Inc. offers ParVivo microfluidic chips system is the world’s first and only pre-seeded chip platform, where researchers can purchase chips that have engineered functional living human tissues on them. Emulate Inc., one of the leaders in the organ-on-chip market industry offers colon-chip, duodenum-chip, brain-chip, lung-chip, kidney-chip, and liver-chip to investigate its mechanisms and evaluate its drug efficacy. These wide range of products offering by market players have further increased accessibility of organ-on-chip across different regions, thus fueling the market growth.
However, high cost of the organ chip device and the development of organ-on-chip technology is still in its nascent stage, and is expected to restrain growth of the market. Furthermore, presence of a variety of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities for the market growth during the forecast period. Conversely, considerable rise in healthcare expenditure across the globe led to rise in the market growth. Emerging economies possess high potential for organ-on-chip. Growth in awareness for animal safety during clinical trials and stringent guidelines by regulatory authorities for these trials surge the organ-on- chip market and is being regarded as a promising technology for the alternative to animal testing and is expected to boost the organ-on-chip market size.
The organ-on-chip market is segmented on the basis of type, and region. Depending on type, it is classified into heart-on-chip, human-on-chip, intestine-on-chip, kidney-on-chip, liver-on-chip, and lung-on-chip. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major players profiled in the report are AxoSim Technologies LLC, BICO Group AB(Visikol), CN Bio Innovations Limited, Elveflow, Emulate, Inc., Insphero AG, Mimetas B.V., Nortis Inc., Organovo Holdings, Inc., and Tara Biosystems.
Organ-on-chip is designed to replicate the natural physiology and mechanical stress that cells in the human body encounter.
The chips have real human cells lining them, and their tiny fluidic channels mimic blood and air movement in the human body. The chips flexibility allows them to mimic breathing patterns and muscle contractions. Each organ chip, including the lung, liver, intestine, or brain, is approximately the size of an battery that is typically used in small electronic devices.. Such devices produce multiple levels of tissues and organ functionalities, which are not possible using conventional 2D and 3D culture systems. Organ-on-chip offers a wide range of applications such as diseases modelling, patient stratification, and phenotypic screening. Researchers can see the organ's operation, behavior, and response at the cellular and molecular level because to the chip's transparency.
This market is majorly driven by increase in prevalence of the chronic disease across the globe, which, in turn, increases the demand for medications, leading to drug discovery, drug development, and animal testing. However, organ-on-chips are looked on as an alternative for animal testing due to stringent regulatory guidelines and its complexity. Wide availability of 3D models for in vitro testing,including lung-on-chip, heart-on-chip, liver-on-chip, and brain-on-chip is significantly driving the growth of the market.
Furthermore, in May 2021, the U.S. Food and Drug Administration (FDA) extendedits research collaboration with CN Bio Innovations Limited, one of the leading developers of single and multi-organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, for another three years to investigate the lung-on-a-chip model for inhaled drug evaluation applications.
Furthermore, growth in demand for personalized medicine, rise in pharmaceutical & biotechnology R&D, and government funding for various drugs, clinical trials for novel entities, and repurposing of the drugs are expected to drive the organ-on-chip market in the forecast period.
Market players have invested in developing organ-on-chip products for lung, heart, kidney, brain, liver, and gut that can aid in several disease treatments. For instance, Nortis Inc. offers ParVivo microfluidic chips system is the world’s first and only pre-seeded chip platform, where researchers can purchase chips that have engineered functional living human tissues on them. Emulate Inc., one of the leaders in the organ-on-chip market industry offers colon-chip, duodenum-chip, brain-chip, lung-chip, kidney-chip, and liver-chip to investigate its mechanisms and evaluate its drug efficacy. These wide range of products offering by market players have further increased accessibility of organ-on-chip across different regions, thus fueling the market growth.
However, high cost of the organ chip device and the development of organ-on-chip technology is still in its nascent stage, and is expected to restrain growth of the market. Furthermore, presence of a variety of products in the pipeline and high market potential in untapped emerging economies are anticipated to serve as attractive opportunities for the market growth during the forecast period. Conversely, considerable rise in healthcare expenditure across the globe led to rise in the market growth. Emerging economies possess high potential for organ-on-chip. Growth in awareness for animal safety during clinical trials and stringent guidelines by regulatory authorities for these trials surge the organ-on- chip market and is being regarded as a promising technology for the alternative to animal testing and is expected to boost the organ-on-chip market size.
The organ-on-chip market is segmented on the basis of type, and region. Depending on type, it is classified into heart-on-chip, human-on-chip, intestine-on-chip, kidney-on-chip, liver-on-chip, and lung-on-chip. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major players profiled in the report are AxoSim Technologies LLC, BICO Group AB(Visikol), CN Bio Innovations Limited, Elveflow, Emulate, Inc., Insphero AG, Mimetas B.V., Nortis Inc., Organovo Holdings, Inc., and Tara Biosystems.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the organ-on-chip market analysis from 2020 to 2030 to identify the prevailing organ-on-chip market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the organ-on-chip market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global organ-on-chip market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Type
- Heart on chip
- Human on chip
- Intestine on chip
- Kidney on chip
- Liver on chip
- Lung on chip
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East
- Africa
Key Market Players
- AxoSim Technologies LLC
- BICO Group AB(Visikol)
- CN Bio Innovations Limited
- Elveflow
- Emulate, Inc.
- Insphero AG
- Mimetas B.V.
- Nortis Inc.
- Organovo Holdings, Inc.
- Tara Biosystems
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: ORGAN-ON-CHIP MARKET, BY TYPE
CHAPTER 5: ORGAN-ON-CHIP MARKET, BY REGION
CHAPTER 6: COMPANY LANDSCAPE
CHAPTER 7: COMPANY PROFILES
LIST OF TABLES
LIST OF FIGURES
Executive Summary
The global organ-on-chip market was valued at $103.44 million in 2020, and is estimated to reach $1.6 billion by 2030, growing at a CAGR of 31.1% from 2021 to 2030. An organ-on-a-chip (OOC) is a microfluidic cell culture device developed using microchip manufacturing methods that contains continuously perfused chambers inhabited by living cells arranged to simulate tissue- and organ-level physiology. This chip develops a narrow channel for the blood and air flow in organs including lung, gut, liver, and heart. Such devices produce multiple levels of tissue and organ functionality, which is not possible using conventional 2D and 3D culture systems. Organ-on-chip offers a wide range of applications such as diseases modelling, patient stratification, and phenotypic screening.Growth of the organ-on-chip market is majorly driven by rise in drug discovery, increase in organ failures, surge in need for organ transplantations, and rise in strategic developments among key players of the market. The global organ-on-chip market benefit from an increase in demand for organ-on-chip devices in the healthcare industry. Organ-on-chip technologies are used in the healthcare industry for real-time imaging and in-vitro analysis of biochemical, genetic, and metabolic activities of living cells in a functional tissue.
Increase in disease load, significantly rise in patient pool, and requirement for personalized treatments have surged the demand for organ-on-chip in drug screening. Drug screening is a cost-effective way for evaluating samples quickly. Organ-on-chip culture systems are used by scientists and researchers to track the effects of drugs in the body. In addition, this approach is used to check drug toxicity or effectiveness in various organs of the body.
Furthermore, in December 2020, Emulate, Inc., a leading provider of innovative in vitro models in the organ-on-chip industry, announced the launch of Emulate Brain-chip, which is intended for neuroinflammatory disease researchers and for drug developers looking to accelerate drug development for neurodegenerative diseases, including Alzheimer's and Parkinson's. Thus, such product launch, collaborations, and partnerships among key players are expected to drive the market growth.
However, high development & manufacturing cost and the technology being in the nascent stage and research being conducted to enhance its success rates are expected to impede the market growth. Conversely, high market potential in the developing emerging economies for R&D, rise in various strategies among governments & key players, and development of pipeline products are expected to provide many opportunities for the organ-on-chip market size growth during the forecast period.
Depending on type, the organ-on-chip market analysis lung-on-chip segment generated maximum revenue in 2020, accounting for21.37 million. The heart-on-chip segment is expected to witness highest CAGR of 32.8% during the forecast period.
Region wise, North America exhibited the global organ-on-chip market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in prevalence of technologically advanced models, presence of key players, and rise in R&D activities for drug discovery & development. However, Asia-Pacific organ-on-chip market size is anticipated to witness notable growth in theorgan-on-chip industry, owing to increase in R&D activities, increase in healthcare investment, and various strategies among the key players.
Companies Mentioned
- AxoSim Technologies LLC
- BICO Group AB(Visikol)
- CN Bio Innovations Limited
- Elveflow
- Emulate, Inc.
- Insphero AG
- Mimetas B.V.
- Nortis Inc.
- Organovo Holdings, Inc.
- Tara Biosystems
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2022 |
| Forecast Period | 2020 - 2030 |
| Estimated Market Value ( USD | $ 103.44 million |
| Forecasted Market Value ( USD | $ 1559.2 million |
| Compound Annual Growth Rate | 31.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
